AstraZeneca: to present its advances in oncology
(CercleFinance.com) - AstraZeneca announces that it will present its new advances in cancer treatment at the WCLC (7-10 Sept.
, San Diego) and ESMO (13-17 Sept., Barcelona) conferences.
The company highlights 'promising' results for its drugs, including Imfinzi, Tagrisso, and new antibody-drug conjugates (ADCs) such as datopotamab deruxtecan.
Overall, the data underscore the importance of early intervention and treatment combinations to improve outcomes in patients with various types of cancer, including lung and bladder cancer.
AstraZeneca also continues to develop innovative therapies, including next-generation immunotherapies and ADCs, aimed at replacing traditional chemotherapy.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
, San Diego) and ESMO (13-17 Sept., Barcelona) conferences.
The company highlights 'promising' results for its drugs, including Imfinzi, Tagrisso, and new antibody-drug conjugates (ADCs) such as datopotamab deruxtecan.
Overall, the data underscore the importance of early intervention and treatment combinations to improve outcomes in patients with various types of cancer, including lung and bladder cancer.
AstraZeneca also continues to develop innovative therapies, including next-generation immunotherapies and ADCs, aimed at replacing traditional chemotherapy.
Copyright (c) 2024 CercleFinance.com. All rights reserved.